Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fauzia Ullah has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and safety of direct oral anticoagulants and low molecular weight heparin for cancer-associated venous thromboembolism in patients with extremes in bodyweight

    by Katy M. Toale, Claire A. Marten, Ashley Crouch, Clark R. Andersen, Fauzia Ullah, Cristhiam Mauricio Rojas Hernandez

    The purpose of this study is to describe the safety and efficacy of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) for the treatment of cancer-associated thrombosis in patients with extreme bodyweights. This was a single center, retrospective cohort study of adult patients on therapy for at least 6 months. The primary efficacy outcome of this study was to describe the time to first recurrent venous thromboembolism (VTE) within 6 months, compared between treatment and across weight cohorts. The primary safety objective was to describe the time to first major bleeding (MB) event within 6 months of starting therapy, between treatment types and among the weight groups. Secondary outcomes included incidence of recurrent VTE, MB, clinically relevant non-major bleeding (CRNMB) and the rate of VTE- or bleeding-related mortality. The time to recurrent VTE was comparable between all groups. In the BMI cohort, the time to first MB was 19.5 times longer for DOACs compared to LMWH in the overweight population (p = 0.007) and to first MB or CRNMB was 11.98 times longer (p = < 0.0001). In the weight cohort, the time to first MB or CRNMB was 14.63 times longer for DOACs compared to LMWH in the overweight population (p = 0.011) and 6.41 times longer in the normal weight population (p = 0.0009). There was an insufficient number of patients in the underweight group to perform statistical analysis. The results suggest that in overweight patients, DOACs have similar efficacy and fewer bleeding complications than LMWHs.

  • Immunotherapy for Head and Neck Squamous Cell Carcinoma: Present and Future Approaches and Challenges

    by Mark D. Orland, Fauzia Ullah, Emrullah Yilmaz, Jessica L. Geiger

    Despite significant progress and improving outcomes in the management of head and neck squamous cell carcinoma (HNSCC), there are few effective treatment options for patients with recurrent or metastatic head and neck squamous cell carcinoma. The advent of immune checkpoint inhibitors has changed the treatment algorithm of head and neck squamous cell carcinoma and are approved in the frontline setting for recurrent and metastatic (R/M) head and neck squamous cell carcinomas. Although promising for some patients, most patients with R/M HNSCC do not derive clinical benefit from currently approved checkpoint inhibitors. Many studies are underway to identify the patient population that would benefit the most from immunotherapy as well as postimmunotherapy treatment failures, including novel combinations of immunomodulatory therapies. In this review, we summarize the clinical development of all major clinical trials of immunotherapy in HNSCC.


  • Open Access

    Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations

    by Jaymeson Gordon, Carlos Bravo-Perez, Luca Guarnera, Serhan Unlu, Naomi Kawashima, Arooj Ahmed, Christopher Haddad, Yasuo Kubota, Ishani Nautiyal, Fauzia Ullah, et al.


  • Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

    by Carmelo Gurnari, Hussein Awada, Simona Pagliuca, Danai Dima, Fauzia Ullah, Naomi Kawashima, Yasuo Kubota, Ceylan Colak, Valeria Visconte, Bhumika J. Patel, et al.

    Thrombophilia is one of the principal features of paroxysmal nocturnal hemoglobinuria (PNH) and constitutes the main cause of disease morbidity/mortality. Anticomplement treatment has revolutionized the natural history of PNH, with control of the hemolytic process and abolition of thrombotic events (TEs). However, no guidelines exist for the management of thromboembolic complications in this setting, with type and duration of anticoagulation depending on individual practices. Besides, a scarcity of data is present on the efficacy of direct oral anticoagulants (DOACs). Herein, we accrued a large real-world cohort of patients with PNH from 4 US centers to explore features, predictors of TE, and anticoagulation strategies. Among 267 patients followed up for a total of 2043 patient-years, 56 (21%) developed TEs. These occurred at disease onset in 43% of cases, involving more frequently the venous system, typically as Budd-Chiari syndrome. Rate of TEs was halved in patients receiving complement inhibitors (21 vs 40 TEs per 1000 patient-years in untreated cases, with a 2-year cumulative incidence of thrombosis of 3.9% vs 18.3%, respectively), and varied according to PNH granulocytes and erythrocytes clone size, type, disease activity parameters, as well as number (≥2 mutations, or less) and variant allelic frequency of PIGA mutations. Anticoagulation with warfarin (39%), DOACs (37%), and low-molecular weight heparin (16%) was administered for a median of 29 months (interquartile range [IQR], 9-61.8). No thrombotic recurrence was observed in 19 patients treated with DOACs at a median observation of 17.1 months (IQR, 8.9-45) whereas 14 cases discontinued anticoagulation without TE recurrence at a median time of 51.4 months (IQR, 29.9-86.8).


  • Open Access

    Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma

    by William Wesson, Danai Dima, Nahid Suleman, Saiful Islam Saif, Carine Tabak, Emerson Logan, James A. Davis, Mary McGann, Fateeha Furqan, Meera Mohan, et al.


  • Open Access

    Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

    by Cindy Hsin-Ti Lin, Muhammad Junaid Tariq, Fauzia Ullah, Aishwarya Sannareddy, Farhan Khalid, Hasan Abbas, Abbas Bader, Christy Samaras, Jason Valent, Jack Khouri, et al.

    Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites. Common manifestations of MM include anemia, renal dysfunction, infection, bone pain, hypercalcemia, and fatigue. Despite numerous recent advancements in the MM treatment paradigm, current therapies demonstrate limited long-term effectiveness and eventual disease relapse remains exceedingly common. Myeloma cells often develop drug resistance through clonal evolution and alterations of cellular signaling pathways. Therefore, continued research of new targets in MM is crucial to circumvent cumulative drug resistance, overcome treatment-limiting toxicities, and improve outcomes in this incurable disease. This article provides a comprehensive overview of the landscape of novel treatments and emerging therapies for MM grouped by molecular target. Molecular targets outlined include BCMA, GPRC5D, FcRH5, CD38, SLAMF7, BCL-2, kinesin spindle protein, protein disulfide isomerase 1, peptidylprolyl isomerase A, Sec61 translocon, and cyclin-dependent kinase 6. Immunomodulatory drugs, NK cell therapy, and proteolysis-targeting chimera are described as well.


  • Open Access

    Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment

    by Fauzia Ullah, Mariam Markouli, Mark Orland, Olisaemeka Ogbue, Danai Dima, Najiullah Omar, Moaath K. Mustafa Ali

    Large granular lymphocytic (LGL) leukemia is a lymphoproliferative disorder characterized by persistent clonal expansion of mature T- or natural killer cells in the blood via chronic antigenic stimulation. LGL leukemia is associated with specific immunophenotypic and molecular features, particularly STAT3 and STAT5 mutations and activation of the JAK-STAT3, Fas/Fas-L and NF-κB signaling pathways. Disease-related deaths are mainly due to recurrent infections linked to severe neutropenia. The current treatment is based on immunosuppressive therapies, which frequently produce unsatisfactory long-term responses, and for this reason, personalized approaches and targeted therapies are needed. Here, we discuss molecular pathogenesis, clinical presentation, associated autoimmune disorders, and the available treatment options, including emerging therapies.


  • Open Access

    Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management

    by Mariam Markouli, Fauzia Ullah, Serhan Unlu, Najiullah Omar, Nerea Lopetegui-Lia, Marissa Duco, Faiz Anwer, Shahzad Raza, Danai Dima

    Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into clinical practice, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, has radically shifted the treatment paradigm. However, despite the promising potential of these therapies for broader application, frequent and significant adverse effects have been reported, both in short- and in long-term settings, requiring increasing awareness and vigilance in the treating team, close monitoring, and prompt interventions with a multidisciplinary approach. In this review, we will discuss the toxicities associated with CAR-T cell and bispecific antibody therapies, focusing on results from major clinical studies and real-world observations. In addition, we will emphasize on effective strategies for prevention, monitoring and management, and provide expert recommendations.


  • Top Cited Papers
    Open Access

    Early-Onset Colorectal Cancer: Current Insights

    by Fauzia Ullah, Ashwathy Balachandran Pillai, Najiullah Omar, Danai Dima, Seema Harichand

    Over the past decade, the incidence of colorectal cancer has increased in individuals under the age of 50 years. Meanwhile, the incidence has gradually decreased in the older population. As described herein, we reviewed the available literature to summarize the current landscape of early-onset colorectal cancer, including risk factors, clinicopathological presentation, genetic makeup of patients, and management. Currently, early-onset colorectal cancer is treated similarly as late-onset colorectal cancer, yet the available literature shows that early-onset colorectal cancer is more aggressive and different, and this remains a significant unmet need. A detailed understanding of early-onset colorectal cancer is needed to identify risk factors for the increased incidence and tailor treatments accordingly.


  • Open Access

    Safety and Effectiveness of Direct Oral Anticoagulants for the Treatment of Gastrointestinal Cancer-Associated Venous Thromboembolism

    by Fauzia Ullah, Juhee Song, Cristhiam M Rojas Hernandez, Michael H Kroll, Carmelita P Escalante, Katy M Toale

    Patients with gastrointestinal cancer (GICA) are at high risk for venous thromboembolism (VTE). Data from randomized clinical trials in cancer-associated VTE suggest that direct oral anticoagulants (DOACs) conferred similar or superior efficacy but a heterogeneous safety profile in patients with GICA. We compared the safety and effectiveness of DOACs in patients with GICA and VTE at MD Anderson Cancer Center. This was a retrospective chart review of patients with GICA and VTE receiving treatment with DOACs for a minimum of 6 months. Primary outcomes were the proportion of patients experiencing major bleeding (MB), clinically relevant non-major bleeding (CRNMB), and recurrent VTE. Secondary outcomes were time to bleeding and recurrent VTE. A cohort of 433 patients with GICA who were prescribed apixaban (n = 300), or rivaroxaban (n = 133) were included. MB occurred in 3.7% (95% confidence interval [CI] 2.1-5.9), CRNMB in 5.3% (95% CI 3.4-7.9), and recurrent VTE in 7.4% (95% CI 5.1-10.3). The cumulative incidence rates of CRNMB and recurrent VTE were not significantly different when comparing apixaban to rivaroxaban. Apixaban and rivaroxaban had a similar risk of recurrent VTE and bleeding and could be considered as anticoagulant options in selected patients with GICA and VTE.